Association of FTH1-Expressing Circulating Tumor Cells With Efficacy of Neoadjuvant Chemotherapy for Patients With Breast Cancer: A Prospective Cohort Study.
Association of FTH1-Expressing Circulating Tumor Cells With Efficacy of Neoadjuvant Chemotherapy for Patients With Breast Cancer: A Prospective Cohort Study.
复制标题
表达fth1的循环肿瘤细胞与乳腺癌患者新辅助化疗疗效的关联：一项前瞻性队列研究
DOI：
10.1093/oncolo/oyad195
复制
发表时间：
2024-01-05
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
循环肿瘤细胞（CTC）的不同表型和基因型与新辅助化疗（NAC）疗效之间的关联仍不确定。本研究旨在评估非转移性乳腺癌患者中 FTH1 基因相关 CTC（F-CTC）有/无上皮间质转化（EMT）标志物的关系，或其动态变化与 NAC 疗效的关系。这项研究招募了 120 名计划接受 NAC 的非转移性乳腺癌患者。在NAC前（T0）、2个周期化疗后（T1）和手术前（T2）检测CTC中的FTH1基因和EMT标志物。使用二元逻辑回归分析评估这些不同类型的 CTC 与病理完全缓解 (pCR) 和保乳手术 (BCS) 率的关联。 T0 时外周血 F-CTC ≥1 是 HER2 阳性患者 pCR 率的独立因素（比值比 [OR]=0.08，95% 置信区间 [CI]，0.01-0.98，P = 0.048）。 T2 时 F-CTC 数量的减少是 BCS 率的独立因素（OR = 4.54，95% CI，1.14-18.08，P = .03）。 NAC 之前的 F-CTC 数量与 NAC 反应不佳有关。 F-CTC 的监测可以帮助临床医生制定个性化的 NAC 方案并为非转移性乳腺癌患者实施 BCS。本文评估了非转移性乳腺癌患者中不同类型的循环肿瘤细胞及其动态变化与新辅助化疗疗效的关系。
The association between different phenotypes and genotypes of circulating tumor cells (CTCs) and efficacy of neoadjuvant chemotherapy (NAC) remains uncertain. This study was conducted to evaluate the relationship of FTH1 gene-associated CTCs (F-CTC) with/without epithelial-mesenchymal transition (EMT) markers, or their dynamic changes with the efficacy of NAC in patients with non-metastatic breast cancer. This study enrolled 120 patients with non-metastatic breast cancer who planned to undergo NAC. The FTH1 gene and EMT markers in CTCs were detected before NAC (T0), after 2 cycles of chemotherapy (T1), and before surgery (T2). The associations of these different types of CTCs with rates of pathological complete response (pCR) and breast-conserving surgery (BCS) were evaluated using the binary logistic regression analysis. F-CTC in peripheral blood ≥1 at T0 was an independent factor for pCR rate in patients with HER2-positive (odds ratio [OR]=0.08, 95% confidence interval [CI], 0.01-0.98, P = .048). The reduction in the number of F-CTC at T2 was an independent factor for BCS rate (OR = 4.54, 95% CI, 1.14-18.08, P = .03). The number of F-CTC prior to NAC was related to poor response to NAC. Monitoring of F-CTC may help clinicians formulate personalized NAC regimens and implement BCS for patients with non-metastatic breast cancer. This article assesses the associations of different types of circulating tumor cells and their dynamic changes with the efficacy of neoadjuvant chemotherapy in patients with non-metastatic breast cancer.
登录
查看更多内容
影响因子：
5.6
作者：
Lu B;Chen XB;Ying MD;He QJ;Cao J;Yang B
通讯作者：
Yang B
DOI：
10.1074/mcp.m113.037176
发表时间：
2014-07
期刊：
Molecular & cellular proteomics : MCP
影响因子：
--
作者：
Liu NQ;De Marchi T;Timmermans AM;Beekhof R;Trapman-Jansen AM;Foekens R;Look MP;van Deurzen CH;Span PN;Sweep FC;Brask JB;Timmermans-Wielenga V;Debets R;Martens JW;Foekens JA;Umar A
通讯作者：
Umar A
影响因子：
3.4
作者：
Kanojia, Deepak;Zhou, Weidong;Chen, Hexin
通讯作者：
Chen, Hexin
影响因子：
44.1
作者：
Tang D;Chen X;Kang R;Kroemer G
通讯作者：
Kroemer G
影响因子：
3.8
作者：
Gorges TM;Tinhofer I;Drosch M;Röse L;Zollner TM;Krahn T;von Ahsen O
通讯作者：
von Ahsen O